The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator

Science

Volumn 323, Issue 5916, 2009, Pages 934-937

  Fontanilla, Dominique ^a   Johannessen, Molly ^a   Hajipour, Abdol R ^b   Cozzi, Nicholas V ^a   Jackson, Meyer B ^a   Ruoho, Arnold E ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b ISFAHAN UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

N,N DIMETHYLTRYPTAMINE; SIGMA 1 OPIATE RECEPTOR; TRYPTAMINE; VOLTAGE GATED SODIUM CHANNEL;

CARDIOLOGY; CELL ORGANELLE; GENETIC ANALYSIS; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; WILD TYPE;

ANIMALS; CELL LINE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; GUINEA PIGS; HALLUCINOGENS; LIGANDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; N,N-DIMETHYLTRYPTAMINE; RATS; RECEPTORS, SIGMA; TRYPTAMINES;

MUS;

EID: 60149107790     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1166127     Document Type: Article

References (31)

1. T. Hayashi, T. P. Su, CNS Drugs 18, 269 (2004).
2. P. Bouchard et al., Eur. J. Neurosci. 7, 1952 (1995).
3. T. P. Su, A. D. Weissman, S. Y. Yeh, Life Sci. 38, 2199 (1986).
4. T. P. Su, E. D. London, J. H. Jaffe, Science 240, 219 (1988).
5. R. A. Wilke et al., J. Physiol. 517, 391 (1999).
6. R. A. Glennon et al., J. Med. Chem. 37, 1214 (1994).
7. F. F. Moebius, R. J. Reiter, M. Hanner, H. Glossmann, Br. J. Pharmacol. 121, 1 (1997).
8. S. A. Barker, J. A. Monti, S. T. Christian, Int. Rev. Neurobiol. 22, 83 (1981).
9. F. Franzen, H. Gross, Nature 206, 1052 (1965).
10. M. S. Jacob, D. E. Presti, Med. Hypotheses 64, 930 (2005).
11. J. Axelrod, Science 134, 343 (1961).
12. J. M. Saavedra, J. Axelrod, Science 175, 1365 (1972).
13. J.M. Beaton, P. E. Morris, Mech. Ageing Dev. 25, 343 (1984).
14. S. A. Burchett, T. P. Hicks, Prog. Neurobiol. 79, 223 (2006).
15. B. Borowsky et al., Proc. Natl. Acad. Sci. U.S.A. 98, 8966 (2001).
16. L. Lindemann et al., Genomics 85, 372 (2005).
17. J. R. Kahoun, A. E. Ruoho, Proc. Natl. Acad. Sci. U.S.A. 89, 1393 (1992).
18. A. Pal et al., Mol. Pharmacol. 72, 921 (2007).
19. Y. Chen, A. R. Hajipour, M. K. Sievert, M. Arbabian, A. E. Ruoho, Biochemistry 46, 3532 (2007).
20. P. J. Lupardus et al., J. Physiol. 526, 527 (2000).
21. H. Zhang, J. Cuevas, J. Pharmacol. Exp. Ther. 313, 1387 (2005).
22. E. Aydar, C. P. Palmer, V. A. Klyachko, M. B. Jackson, Neuron 34, 399 (2002).
23. R. A. Wilke et al., J. Biol. Chem. 274, 18387 (1999).
24. C. Kennedy, G. Henderson, Neuroscience 35, 725 (1990).
25. H. Zhang, J. Cuevas, J. Neurophysiol. 87, 2867 (2002).
26. M. A. Johannessen, A. Ramos-Serrano, S. Ramachandran, A. E. Ruoho, M. B. Jackson, "Sigma receptor modulation of voltage-dependent sodium channels," Program No. 466.22, Annual Neuroscience Meeting, San Diego, CA, 5 November 2007.
27. F. Langa et al., Eur. J. Neurosci. 18, 2188 (2003).
28. P. Jenner, C. D. Marsden, C. M. Thanki, Br. J. Pharmacol. 69, 69 (1980).
29. R. R. Matsumoto, B. Pouw, Eur. J. Pharmacol. 401, 155 (2000).
30. T. Hayashi, T. P. Su, Cell 131, 596 (2007).
31. 125I]-IACoc, respectively. Supported by the Molecular and Cellular Pharmacology (MCP) Graduate Program training grant from NIH T32 GM08688 and by the NIH Ruth L. Kirschstein National Research Service Award (NRSA) (F31 DA022932) from the National Institute on Drug Abuse (to D.F.). This work was funded by NIH grants R01 MH065503 (to A.E.R.) and NS30016 (to M.B.J.).